tiprankstipranks
Trending News
More News >
Liminatus Pharma (LIMN)
NASDAQ:LIMN
US Market
Advertisement

Liminatus Pharma (LIMN) Income Statement

Compare
30 Followers

Liminatus Pharma Income Statement

Last quarter (Q1 2025), Liminatus Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, Liminatus Pharma's net income was $-255.00. See Liminatus Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 2.91M$ 4.82M$ 2.71M$ 2.53M$ 7.81K
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00$ 7.81K
EBITDA
$ -405.00$ -4.81M$ -2.71M$ 4.37M-
Operating Income
$ -405.00$ -4.82M$ -2.71M$ -2.53M$ -7.81K
Other Income/Expenses
$ 0.00$ -165.00K$ -219.00K$ 6.90M$ 0.00
Pretax Income
$ -405.00$ -4.98M$ -2.93M$ 4.37M$ -7.81K
Net Income
$ -405.00$ -4.98M$ -2.93M$ 4.37M$ -7.81K
Per Share Metrics
Basic EPS
$ -4.05$ -0.19$ -0.11$ 0.13$ 0.00
Diluted EPS
$ -4.05$ -0.19$ -0.11$ 0.13$ 0.00
Weighted Average Shares Outstanding
100.00 26.71M 26.71M 34.50M 6.90M
Weighted Average Shares Outstanding (Diluted)
100.00 26.71M 26.71M 34.50M 6.90M
Currency in USD

Liminatus Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis